Dynavax Technologies Corporation·Healthcare

Blair William and Co. IL cut its position in Dynavax Technologies Corporation (NASDAQ: DVAX) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,228,609 shares of the biopharmaceutical company's stock after selling 51,038 shares during the period.

AXQ Capital LP purchased a new position in Dynavax Technologies Corporation (NASDAQ: DVAX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 35,615 shares of the biopharmaceutical company's stock, valued at approximately $354,000. Several other large investors also recently bought and

NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE: CIEN) will replace Dayforce Inc. (NYSE: DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE: ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P.

AlphaQuest LLC grew its holdings in Dynavax Technologies Corporation (NASDAQ: DVAX) by 109.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 173,140 shares of the biopharmaceutical company's stock after purchasing an additional 90,641 shares during the period. AlphaQuest LLC

114,000 shares were exercised and sold on Jan. 15, 2026, for a transaction value of approximately ~$1.8 million, at a weighted average price of around $15.64 per share. The entire trade was executed via direct holdings through an option exercise and immediate sale, with no indirect entities involved.

Dynavax Technologies Corporation (NASDAQ: DVAX - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Healthcare
Drug Manufacturers - Specialty & Generic
405
2004-02-19
0.93